FDA puts commissioner’s priority voucher framework on ice
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme,…
13 Nov 2026
Neurosterix pockets $105m to advance neuropsychiatry pipeline
Swiss biotech company Neurosterix has banked $105m in a Series B funding round to push its range of neuropsychiatric candidates further down the pipeline. The financing, which was led by…
13 Nov 2026
BMS sets unified research and development structure for 2027
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027. The company’s executive vice president and…
13 Nov 2026
Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1. The therapy is an oral orexin receptor 2…
12 Nov 2026
Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
Eli Lilly has beaten its staunch obesity rival Novo Nordisk to market in China by securing an approval for its weight loss pill orforglipron from the country’s National Medical Products…
12 Nov 2026
Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
With an eye on entering the obesity market dominated by Eli Lilly, Pfizer has secured $1.5bn from Blackstone Life Sciences to spur clinical development of its monthly glucagon-like peptide-1 receptor…
12 Nov 2026
Beyond GLP-1RA’s: Novel mechanisms and combos to shape future of obesity market
In recent years, the emergence of the incretin drug class has revolutionised the cardiometabolic treatment space, as doctors increasingly prescribe weight loss medications for the long-term management of obesity and…